Midomafetamine
- Generic Name
- Midomafetamine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C11H15NO2
- CAS Number
- 42542-10-9
- Unique Ingredient Identifier
- KE1SEN21RM
- Background
An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.
- Indication
Clinical trials are now testing the therapeutic potential of MDMA for post-traumatic stress disorder (PTSD) and anxiety associated with terminal cancer. MDMA is one of the four most widely used illicit drugs in the U.S.
- Associated Conditions
- -
- Associated Therapies
- -
Psychedelic drugs have great therapeutic promise. But Question 4 goes too far.
Question 4 proposes legalizing home growing and unregulated consumption of five psychedelic drugs, despite health risks. The board recommends voting no, suggesting a committee of experts to create a regulated framework. FDA approval is crucial for ensuring drug safety and efficacy. The initiative includes therapeutic centers with trained facilitators, but allowing home grows contradicts rigorous oversight. If passed, strict regulations are needed to protect public safety.
Canadian Biotech Company to Supply MDMA for Pending HMS Clinical Trial
PharmAla Biotech signed a contract to supply MDMA to Harvard Medical School for a clinical trial on borderline personality disorder. The trial, pending grant funding, aims to study MDMA's mechanistic effects. PharmAla supports researchers with a customer-centric approach, facilitating the complex regulatory process required for MDMA trials.
Delhi police launch hunt for drug peddlers
Synthetic drugs like MDMA are becoming prevalent in Delhi-NCR, with Dwarka and Greater Noida as hotspots for narcotics consumption and smuggling. Delhi Police recently busted an inter-state supply network, seizing 1,200 grams of hashish and 90 grams of heroin. The accused, Ajay Lal, a 63-year-old man, was involved in drug trade after serving time in Nepal for cheating.
How One Biotech Is Using FDA 505(b)(2) To Get Drugs To Patients Quicker And Cheaper
Terran Biosciences, led by CEO Sam Clark, is leveraging the FDA's 505(b)(2) pathway to expedite the development of TerXT, a new treatment for schizophrenia. By referencing data from Bristol Myers Squibb's Cobenfy, Terran aims to create a once-daily oral dose and a long-acting injectable version of TerXT, addressing Cobenfy's limitations. This approach, which includes the use of prodrugs, aims to provide more affordable and accessible treatment options for patients.
PharmAla to supply the University of Texas, San Antonio, with novel dosage form of LaNeo™ MDMA
PharmAla Biotech contracted to supply MDMA for a clinical trial at the University of Texas, San Antonio, aiming to develop a new dosage form. The company also announced the publication of a patent related to its APA-01 novel molecular entity, part of its IP strategy.
Wisconsin is on the front lines of psychedelic research that could reach millions
Psilocybin, found in magic mushrooms, shows promise in treating clinical depression when combined with therapy, according to Wisconsin researchers. Estimates suggest 6 million U.S. patients could benefit if approved, though challenges include cost and regulatory hurdles.
Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple
Studies highlight prevalence of psychiatric disorders among cancer patients, psychological distress by cancer site, and management of anxiety and depression in survivors, with a focus on screening, assessment, and care of anxiety and depressive symptoms. Emerging treatments include ketamine and psychedelics like psilocybin, which show potential for rapid symptom reduction and neuroplasticity enhancement.
GBI arrests Maysville man in drug trafficking investigation
Nicholas Armand, 25, of Maysville, was arrested and charged with possession of MDMA, psilocybin mushrooms, marijuana with intent to distribute, and two counts of firearm possession during a felony. The charges followed a search warrant execution by Commerce Police and ARDEO on October 1, resulting in the seizure of firearms and drugs.
MDMA was hyped as a promising treatment for PTSD – what went wrong?
MDMA, traditionally used recreationally, faces challenges in medical approval for therapies.
PharmAla to supply Harvard Medical School's Maclean Hospital with LaNeo MDMA
PharmAla Biotech Holdings Inc. contracted as MDMA supplier for Harvard’s Maclean Hospital clinical trial. PharmAla offers rapid support for clinical trial registrations and IRB approvals. Attending CPHI conference in Milan to meet potential European distribution partners.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath